publication date: Aug. 3, 2017
CCL July 2017 - Aug. 3, 2017
July 2017PDF


Hematologic Malignancies

Oral enasidenib demonstrates durable CRs in IDH2 mutant relapsed, refractory AML

Agios Pharmaceuticals Inc. published efficacy and safety data from the ongoing phase I/II dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia and an isocitrate dehydrogenase-2 mutation.

Novartis data shows half of eligible Ph+ CML-CP patients remain in treatment-free remission after stopping Tasigna

Novartis CTL019 6-month follow-up data show durable remission rates in children with r/r B-cell ALL

NEJM publishes analysis of midostaurin phase III RATIFY trial in newly diagnosed FLT3-mutated AML


Lung cancer

Continue reading CCL July 2017
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.